Cargando…
PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL)
| Autores principales: | , , , , , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Lippincott Williams & Wilkins
2022
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431472/ http://dx.doi.org/10.1097/01.HS9.0000850364.78915.d9 |
| _version_ | 1784780064917815296 |
|---|---|
| author | Barrientos, J. C. Barr, P. M. Mato, A. R. Tam, C. S. Ghia, P. Moreno, C. Kay, N. E. Siddiqi, T. Szafer-Glusman, E. Zhou, C. Neumayr, L. Krigsfeld, G. Wierda, W. G. Shanafelt, T. |
| author_facet | Barrientos, J. C. Barr, P. M. Mato, A. R. Tam, C. S. Ghia, P. Moreno, C. Kay, N. E. Siddiqi, T. Szafer-Glusman, E. Zhou, C. Neumayr, L. Krigsfeld, G. Wierda, W. G. Shanafelt, T. |
| author_sort | Barrientos, J. C. |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-9431472 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2022 |
| publisher | Lippincott Williams & Wilkins |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-94314722022-08-31 PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Barrientos, J. C. Barr, P. M. Mato, A. R. Tam, C. S. Ghia, P. Moreno, C. Kay, N. E. Siddiqi, T. Szafer-Glusman, E. Zhou, C. Neumayr, L. Krigsfeld, G. Wierda, W. G. Shanafelt, T. Hemasphere Publication Only Lippincott Williams & Wilkins 2022-06-23 /pmc/articles/PMC9431472/ http://dx.doi.org/10.1097/01.HS9.0000850364.78915.d9 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access Abstract Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially. |
| spellingShingle | Publication Only Barrientos, J. C. Barr, P. M. Mato, A. R. Tam, C. S. Ghia, P. Moreno, C. Kay, N. E. Siddiqi, T. Szafer-Glusman, E. Zhou, C. Neumayr, L. Krigsfeld, G. Wierda, W. G. Shanafelt, T. PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_full | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_fullStr | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_full_unstemmed | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_short | PB1878: CROSS-TRIAL ANALYSIS OF FIXED-DURATION IBRUTINIB (I) PLUS VENETOCLAX (V) VS FLUDARABINE (F), CYCLOPHOSPHAMIDE (C), AND RITUXIMAB (R) AS FIRST-LINE TREATMENT FOR CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) |
| title_sort | pb1878: cross-trial analysis of fixed-duration ibrutinib (i) plus venetoclax (v) vs fludarabine (f), cyclophosphamide (c), and rituximab (r) as first-line treatment for chronic lymphocytic leukemia (cll) |
| topic | Publication Only |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9431472/ http://dx.doi.org/10.1097/01.HS9.0000850364.78915.d9 |
| work_keys_str_mv | AT barrientosjc pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT barrpm pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT matoar pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT tamcs pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT ghiap pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT morenoc pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT kayne pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT siddiqit pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT szaferglusmane pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT zhouc pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT neumayrl pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT krigsfeldg pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT wierdawg pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll AT shanafeltt pb1878crosstrialanalysisoffixeddurationibrutinibiplusvenetoclaxvvsfludarabinefcyclophosphamidecandrituximabrasfirstlinetreatmentforchroniclymphocyticleukemiacll |